

In the claims:

1. (Previously Presented) A method of treating the psychophysiological effects of stress including anxiety comprising the step of applying to the central nervous system a therapeutically effective amount of an inhibitor of dipeptidyl peptidase IV (DP IV) enzyme or of DP IV-like enzyme whereby enzymatic activity of said enzyme is reduced.

2. (Currently Amended) A method for reducing degradation of the endogenous CNS-localized neuropeptide Y (NPY) and other substrates sharing similar properties as neuropeptide Y for the treatment of psychophysiological effects of stress, comprising the step of providing to the site where such degradation is desired applying to the central nervous system a therapeutically effective amount of a competitive inhibitor of the dipeptidyl peptidase (DP IV) or of DP IV - like enzyme.

3. (Previously Presented) The method of claim 1 wherein application of said inhibitor results in therapy of psychosomatic, depressive and neuropsychiatric diseases selected from the group consisting of anxiety disorders, depression, insomnia, chronic fatigue, schizophrenia, epilepsy, eating disorders, spasm and chronic pain.

4. (Previously Presented) The method of claim 1 wherein said inhibitors is present in a physiologically compatible drug delivery vehicle.

5. (Previously Presented) The method of claim 1 wherein said inhibitor is formulated as prodrugs of the free inhibitors.

6. (Currently Amended) The method of claim 1 wherein said DP-IV-inhibitors inhibitor of dipeptidyl peptidase IV are applied parenterally, enteraly, orally, by inhalation or suppository.

7. (Previously Presented) The method of claim 2 wherein said inhibitor is present in a physiologically compatible drug delivery vehicle.

8. (Previously Presented) The method of claim 2 wherein said inhibitor is formulated as prodrugs of the free inhibitors.

9. (Previously Presented) The method of claim 3 wherein said inhibitor is formulated as prodrugs of the free inhibitors.

10. (Previously Presented) The method of claim 2 wherein said DP IV-inhibitor is applied parenterally, enteraly, orally, by inhalation or suppository.

11. (Previously Presented) The method of claim 3 wherein said DP IV-inhibitor is applied parenterally, enteraly, orally, by inhalation or suppository.

12. (Previously Presented) The method of claim 4 wherein said DP IV-inhibitor is applied parenterally, enteraly, orally, by inhalation or suppository.

13. (Previously Presented) The method of claim 8 wherein said DP IV-inhibitor is applied parenterally, enteraly, orally, by inhalation or suppository.